

Tullio Torelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3289029/publications.pdf>

Version: 2024-02-01

40
papers

1,039
citations

361296

20
h-index

414303

32
g-index

42
all docs

42
docs citations

42
times ranked

1081
citing authors

#	ARTICLE	IF	CITATIONS
1	The Relationship between Characteristics of Inguinal Lymph Nodes and Pelvic Lymph Node Involvement in Penile Squamous Cell Carcinoma: A Single Institution Experience. <i>Journal of Urology</i> , 2014, 191, 977-982.	0.2	75
2	Proof of Activity of Anti-“Epidermal Growth Factor Receptor” Targeted Therapy for Relapsed Squamous Cell Carcinoma of the Penis. <i>Journal of Clinical Oncology</i> , 2011, 29, e650-e652.	0.8	74
3	Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes. <i>Annals of Oncology</i> , 2015, 26, 657-668.	0.6	71
4	First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study. <i>BJU International</i> , 2018, 121, 348-356.	1.3	70
5	A Combination of Cisplatin and 5-Fluorouracil With a Taxane in Patients Who Underwent Lymph Node Dissection for Nodal Metastases From Squamous Cell Carcinoma of the Penis: Treatment Outcome and Survival Analyses in Neoadjuvant and Adjuvant Settings. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 323-330.	0.9	59
6	Towards the definition of the best management and prognostic factors of teratoma with malignant transformation: a single-institution case series and new proposal. <i>BJU International</i> , 2011, 107, 1088-1094.	1.3	54
7	Long-Term Followup and Clinical Characteristics of Testicular Leydig Cell Tumor: Experience With 24 Cases. <i>Journal of Urology</i> , 2006, 176, 2040-2043.	0.2	47
8	Retroperitoneal Lymph Node Dissection with No Adjuvant Chemotherapy in Clinical Stage I Nonseminomatous Germ Cell Tumours: Long-Term Outcome and Analysis of Risk Factors of Recurrence. <i>European Urology</i> , 2010, 58, 912-918.	0.9	47
9	Clinical Outcome in Testicular Sex Cord Stromal Tumors: Testis Sparing vs Radical Orchiectomy and Management of Advanced Disease. <i>Urology</i> , 2015, 85, 402-406.	0.5	47
10	Systemic Preoperative Chemotherapy with Cisplatin, Methotrexate and Vinblastine for Locally Advanced Bladder Cancer: Local Tumor Response and Early Followup Results. <i>Journal of Urology</i> , 1991, 145, 741-743.	0.2	40
11	Persistent CD30 Expression by Embryonal Carcinoma in the Treatment Time Course: Prognostic Significance of a Worthwhile Target for Personalized Treatment. <i>Journal of Urology</i> , 2013, 190, 1919-1924.	0.2	36
12	Long-term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ cell tumours. <i>BJU International</i> , 2009, 104, 340-346.	1.3	34
13	Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases. <i>Clinical and Experimental Nephrology</i> , 2012, 16, 464-467.	0.7	33
14	Prognostic Factors of Adjuvant Taxane, Cisplatin, and 5-Fluorouracil Chemotherapy for Patients With Penile Squamous Cell Carcinoma After Regional Lymphadenectomy. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 518-523.	0.9	28
15	Combination of Paclitaxel, Cisplatin, and Gemcitabine (TPG) for Multiple Relapses or Platinum-Resistant Germ Cell Tumors: Long-Term Outcomes. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 63-69.e1.	0.9	27
16	A Prognostic Model Including Pre- and Postsurgical Variables to Enhance Risk Stratification of Primary Mediastinal Nonseminomatous Germ Cell Tumors: The 27-Year Experience of a Referral Center. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 87-93.e1.	0.9	27
17	Interim Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography for Early Metabolic Assessment of Therapeutic Response to Chemotherapy for Metastatic Transitional Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 433-439.	0.9	24
18	Relationship between lymph node ratio and cancer-specific survival in a contemporary series of patients with penile cancer and lymph node metastases. <i>BJU International</i> , 2015, 116, 727-733.	1.3	23

#	ARTICLE	IF	CITATIONS
19	Concordance and Prediction Ability of Original and Reviewed Vascular Invasion and Other Prognostic Parameters of Clinical Stage I Nonseminomatous Germ Cell Testicular Tumors After Retroperitoneal Lymph Node Dissection. <i>Journal of Urology</i> , 2011, 186, 1298-1302.	0.2	21
20	Laparoscopic Retroperitoneal Lymph Node Dissection for Clinical Stage I Nonseminomatous Germ Cell Tumors of the Testis: Safety and Efficacy Analyses at a High Volume Center. <i>Journal of Urology</i> , 2018, 199, 741-747.	0.2	21
21	Micturitional dysfunction after anterior resection for rectal cancer. <i>Diseases of the Colon and Rectum</i> , 1988, 31, 707-709.	0.7	20
22	Laparoscopic Postchemotherapy Retroperitoneal Lymph-Node Dissection Can Be a Standard Option in Defined Nonseminomatous Germ Cell Tumor Patients. <i>Journal of Endourology</i> , 2016, 30, 1112-1119.	1.1	20
23	Postchemotherapy Lymphadenectomy in Patients With Metastatic Urothelial Carcinoma: Long-Term Efficacy and Implications for Trial Design. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 80-86.e1.	0.9	17
24	Long-Term Efficacy and Safety Outcomes of Modified (Simplified) MVAC (Methotrexate/Vinblastine/Doxorubicin/Cisplatin) as Frontline Therapy for Unresectable or Metastatic Urothelial Cancer. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 203-209.e1.	0.9	15
25	Modified cisplatin, etoposide, and ifosfamide (PEI) salvage therapy for male germ cell tumors: long-term efficacy and safety outcomes. <i>Annals of Oncology</i> , 2013, 24, 2887-2892.	0.6	14
26	Five-Year Results of Neoadjuvant Cisplatin, Methotrexate and Vinblastine Chemotherapy plus Radical Cystectomy in Locally Advanced Bladder Cancer. <i>European Urology</i> , 1995, 28, 102-107.	0.9	13
27	Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogation. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 332.e19-332.e24.	0.8	12
28	Immunohistochemistry to Enhance Prognostic Allocation and Guide Decision-Making of Patients With Advanced Urothelial Cancer Receiving First-Line Chemotherapy. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 171-177.e1.	0.9	9
29	Neoadjuvant sorafenib, gemcitabine, and cisplatin administration preceding cystectomy in patients with muscle-invasive urothelial bladder carcinoma: An open-label, single-arm, single-center, phase 2 study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 8.e1-8.e8.	0.8	8
30	Sacral Chordoma and Rehabilitative Treatment of Urinary Disorders. <i>Tumori</i> , 1988, 74, 475-478.	0.6	7
31	Neoadjuvant CMV Chemotherapy plus Radical Cystectomy in Locally Advanced Bladder Cancer: The Impact of Pathologic Response on Long-Term Results. <i>Tumori</i> , 1996, 82, 463-469.	0.6	7
32	CT-guided percutaneous cryoablation of renal masses in selected patients. <i>Radiologia Medica</i> , 2012, 117, 593-605.	4.7	7
33	Treatment of Carcinoma In Situ of the Glans Penis With Topical Imiquimod Followed by Carbon Dioxide Laser Excision. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e483-e487.	0.9	7
34	Quality of Life and Pain Control following Laparoscopic Retroperitoneal Lymph Node Dissection in Early-stage Nonseminoma. <i>Tumori</i> , 2015, 101, 650-656.	0.6	6
35	Activity of pazopanib in chemo-resistant patients with germ cell tumors (GCT): First results of the open-label, single-group, phase II PAZOTEST-01 trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 376-376.	0.8	5
36	Clinical Outcomes of Metastatic Poor Prognosis Germ Cell Tumors: Current Perspective From a Referral Center. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 385-391.e1.	0.9	4

#	ARTICLE	IF	CITATIONS
37	Etoposide, Methotrexate, and Dactinomycin Alternating With Cyclophosphamide and Vincristine (EMACO) for Male Patients With HCG-expressing, Chemoresistant Germ Cell Tumors. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 60-65.	0.6	4
38	Surgery of locally advanced and metastatic kidney cancer after tyrosine kinase inhibitors therapy: single institute experience. Tumori, 2018, 104, 388-393.	0.6	2
39	973 LAPAROSCOPIC RETROPERITONEAL LYMPH-NODE DISSECTION (L-RPLND): EVOLUTION TOWARDS A SINGLE-STRATEGY MANAGEMENT IN CLINICAL STAGE I (CS I) NON-SEMINOMATOUS GERM-CELL TUMORS OF THE TESTIS (NSGCTT). Journal of Urology, 2011, 185, .	0.2	1
40	Prostatic metastases from testicular nonseminomatous germ cell cancer: two case reports and a review of the literature. Tumori, 2013, 99, e203-7.	0.6	1